Clinical Trial

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 3, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main aim of this clinical trial is to assess the safety and efficacy of a single dose of PN20 in treatment of thrombocytopenia in adult patients with chronic liver disease undergoing an elective procedure. The main questions it aims to answer are: * How effective is PN20 in treating thrombocytopenia in patients with chronic liver disease? * Is PN20 safe in these patients? Participants will * Receive a single subcutaneous injections of PN20 or placebo according to weight before an elective procedure, * Visit the clinic for assessment.
Trial Details
NCT Number NCT07446491
Lead Sponsor Chongqing Peg-Bio Biopharm Co., Ltd.
Conditions Thrombocytopenia Associated With Chronic Liver Disease
Enrollment 54 participants
Start Date 2025-06-06
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-06-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-03